Biotech · Private company
Kinevant Sciences GmbH
Track this companyFree. Adds Kinevant Sciences GmbH to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- GimsilumabPhase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- NamilumabPhase 2 · Sarcoidosis, CardiacClinicalTrials.gov · fetched Nov 12, 2026
- NamilumabPhase 2 · Sarcoidosis, PulmonaryClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary SarcoidosisPHASE2 · TERMINATED · started Aug 31, 2022ClinicalTrials.gov NCT05314517 · fetched Nov 12, 2026
- A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac SarcoidosisPHASE2 · TERMINATED · started Aug 23, 2022ClinicalTrials.gov NCT05351554 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)PHASE2 · COMPLETED · started Apr 15, 2020ClinicalTrials.gov NCT04351243 · fetched Nov 12, 2026